comprehensive -WSS

comprehensive

author：leisure time 2025-10-02 14:51:34 - browse：59652

Medicare and money photo illustration. — Adobe

WASHINGTON — A week after the Food and Drug Administration granted full, traditional approval to a new Alzheimer’s treatment, insurers are finalizing their plans to cover it as well as associated scans and diagnostic tests.

Medicare will cover most patients eligible for Leqembi, a new treatment developed by Eisai and Biogen to help slow the progression of Alzheimer’s disease. The drug, which has modest benefits, has potentially serious side effects for some patients including brain swelling and bleeding.

Medicare told STAT that it would cover brain scans and genetic testing that will help screen for and monitor potential side effects. Medicare already covers one amyloid PET scan per lifetime, but the agency is reconsidering that policy and plans to release a new proposed policy “soon,” an agency spokesperson said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

WSS

Pharma patents targeted by Biden in move to slash drug prices

Millions may soon lose Medicaid when they don't have to

Millions may soon lose Medicaid when they don't have to

Science's Marcia McNutt, trailblazer for women, encounters sexism scandal

Patients' immediate access to test results puts radiologists in a bind

Eli Lilly’s Mounjaro succeeds in second weight

hotspot

comprehensive

Wikipedia

Wildfire smoke exposes gaps in outdoor worker protections

Mom launches Girl Scout troop for LGBTQ youth in Texas

ChatGPT in medicine: STAT answers readers' burning questions

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

Apple is now the first public company to be valued at $3 trillion

Tennessee law changes starting July 1 will restrict trans health care and fund more school safety

As demand for Covid shots wanes, Moderna seeks its next success

Altering the blood type of lungs raises potential for universal organs for transplants

Wildfire smoke exposes gaps in outdoor worker protections

Inside the rise of 'mukbang' eating videos

hotspot

Science's Marcia McNutt, trailblazer for women, encounters sexism scandal

Why sickle cell disease is getting the first CRISPR treatment

Novo pauses ads for weight loss drug Wegovy amid demand

FDA approves first new drug developed for postpartum depression

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

hotspot

leisure time

focus

explore